Nothing is ever guaranteed
Even "publicly adverting to fill a job placement, but already offered the job to the preferred candidate", you still need to go through a procurement process and possibly an objection process as well
But, SI would have had good discussions with FDA about the possible process and approval pathways.
He's conservative, so would have looked at all the ramifications - from a failed trial to pricing...
And yet Mesoblast decided to proceed with the Covid-19 - why is that?
My thinking:
- Confidence in the Rem-L product, via the data that we already have
- Understanding of the pharmacoeconomics and what reimbursement we are going to get
- Accept the risks, but the transformational publicity associated with Covid-19, is just too hard to let pass
- +++
SI & Mesoblast would have weighted all this up and said - let's do it!
... and here we are
- Forums
- ASX - By Stock
- MSB
- Ann: Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
Ann: Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment, page-80
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B |
Open | High | Low | Value | Volume |
$1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5127 | $1.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.57 | 39613 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5127 | 1.565 |
3 | 15000 | 1.560 |
1 | 507 | 1.550 |
2 | 8950 | 1.545 |
5 | 81611 | 1.540 |
Price($) | Vol. | No. |
---|---|---|
1.570 | 39613 | 3 |
1.575 | 6173 | 1 |
1.580 | 119061 | 10 |
1.585 | 5500 | 1 |
1.590 | 91149 | 4 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online